Pharmaceutical Companies Fighting Marijuana Rescheduling? Here's Why

Send us Fan Mail DOJ just filed a brief telling the D.C. Circuit to deny the anti-rescheduling stay motion — and the argument is brutal: the drug-testing lobby and cannabinoid pharma challengers are not protecting public health, they are protecting “pocketbook interests.” This week on Cannabis Legalization News, Tom and Miggy break down the DOJ’s new marijuana rescheduling brief, the live DEA hearing where the government is now arguing FOR Schedule III, Illinois’ new SB 3222 cannabis and hem...